ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple MyelomaSOUTH...
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment...
SAN CARLOS, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (Nasdaq: APGN), a clinical-stage company focused on developing innovative...
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance...
Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of...
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology...
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global...
Qualigen Therapeutics, Inc. Benedict M. AbuganCARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”...
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment...
Acquisition of Worldwide Rights to Proleukin® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial...
Daniel Shea appointed as interim Chief Financial Officer William Keyes hired as Senior Vice President, US Commercial Sales, AI NASHUA,...
Matteo Levisetti, M.D., promoted to Chief Medical Officer, effective January 17, 2023Acting CMO Kenneth Pienta, M.D., to transition to a...
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK,...
BURNABY, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific...
Achieves Record 4x Improvement in Time-To-Result to Provide Test Results in Under 1 MinuteNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) --...
Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated...
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy Phase I/II trial will assess safety and efficacy...
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused...
Bavituximab plus pembrolizumab combination achieved a 62.5% response rate in biomarker positive subgroup of hepatocellular cancer patients Data reinforce the...